BPC-157: Evidence, Risks and What Users Report
Also known as:
often mentioned with:
Related topics
BPC-157 is the most discussed healing peptide in the community archive — appearing in more confessions than any other compound in its category. The community's relationship with it is long and detailed: thousands of accounts covering tendon repair, gut healing, joint injuries, and systemic recovery. This guide is not a clinical overview. It is a synthesis of what the community has learned through use: what works, what doesn't, the debates that remain unresolved, and the realistic expectations that experienced users describe.
What BPC-157 Is and What the Community Uses It For
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in gastric juice. Its stability in the GI environment was the original finding that drove early research interest — it survives the acidic stomach environment intact, which is unusual for peptides. Community accounts use it across three primary domains. First: musculoskeletal injury — tendon, ligament, and joint healing. Second: gut health — leaky gut, IBD, post-antibiotic microbiome disruption, NSAID damage. Third: systemic recovery — surgical healing, overuse injuries, and inflammation management. A fourth, smaller cluster of accounts uses it for neurological concerns — traumatic brain injury recovery and neuroprotective effects — though this remains a niche relative to the healing use cases.
BPC-157 for Injury Recovery — What the Community Reports
Injury reports are BPC-157's largest category, dominated by tendons — Achilles, patellar, rotator cuff, elbow. The arc reports describe: less pain first, then gradual functional improvement over weeks. Combined use with TB-500 is common. The evidence base is animal research, the compound is unapproved and prohibited in sport, and serious injuries need imaging and a clinician.
BPC-157 for Gut Health — What the Community Reports
Gut healing is the second major use in reports: IBS, Crohn's, 'leaky gut' and NSAID or alcohol irritation. Reports argue oral forms suit the gut, based on animal studies showing stability in gastric juice. Acute irritation reports describe fast improvement; chronic conditions show variable outcomes. Inflammatory bowel disease needs a gastroenterologist.
Why There Is No Standard BPC-157 Dose
This site does not publish BPC-157 doses, frequencies or cycle lengths. BPC-157 is not an approved medicine in Canada, the US or the EU, so there is no validated human dose. Independent testing has repeatedly found wrong amounts, impurities and contamination, so a number written in a story would not mean the same thing from vial to vial. In 2023 the FDA placed BPC-157 in compounding Category 2 (possible significant safety risks); it was moved off in April 2026 after the nomination was withdrawn, which is not a safety finding and does not make it compoundable.
Side Effects and Safety — What the Community Archive Shows
In this archive BPC-157 reports describe mainly mild effects: nausea, site irritation, occasional dreams; some describe no effect at all. The theoretical concern in discussion is angiogenesis — new blood-vessel growth is the proposed healing mechanism, which raises questions for anyone with cancer or a cancer history. That concern comes from mechanism, not observed outcomes, and there is no long-term human safety data.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
What is BPC-157?
BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide based on a fragment of a protein found in gastric juice. People search it for tendon, gut and injury recovery. It is not an approved medicine in the United States or Canada: the FDA has not approved it, and Health Canada has not authorized it as a drug. As of 11 November 2026 this hub lists 77 published reports. Those stories are mixed, often include other compounds, and are not a substitute for clinical evidence. This is not a dosing recommendation.
What the research says, and its limits
Most BPC-157 research is in animals and cell cultures, where it has been linked to signals of tendon, ligament, muscle and gut repair. There are no published randomised controlled trials in people. The human literature is limited to small case series and a 2025 pilot safety study in which two adults received intravenous infusions without reported side effects — far too small to show safety or benefit.
In 2023 the FDA placed BPC-157 in Category 2 of its interim compounding policy (bulk substances that may present significant safety risks), citing possible immune reactions, impurities and a lack of human safety data. In April 2026 it was moved off Category 2 because the nomination was withdrawn — not because the FDA found it safe — and it was not added to the list of substances pharmacies may compound from. It is named as an example under WADA's S0 non-approved substances category and is prohibited at all times in sport. Last reviewed: November 11, 2026.
What BPC-157 confessions describe
Injury recovery dominates: a torn rotator cuff (#24), post-surgery foot and knee recovery (#20, #48), and fast relief of knee pain (#272). Most of these writers also used TB-500 or other peptides, so effects cannot be separated.
Gut stories are the second theme — long-standing reflux (#46) and IBS (#203). A substantial minority say they felt nothing after full courses (#116, #179), and some describe side effects such as heart-rate changes (#120). These are anonymous accounts, not evidence; healing after injury often improves with time and rehab alone. Related pages: BPC-157 for inflammation and BPC-157 for healing.
Anonymous BPC-157 reports
If you have used BPC-157, including runs where nothing happened, submit the account.
Submit yoursCommunity Q&A
- Is BPC-157 FDA approved?
- No. It has never been approved by the FDA, and Health Canada has not authorized it as a drug. The FDA placed it in compounding Category 2 in 2023; it was moved off in April 2026 after the nomination was withdrawn, without any safety finding or approval, and it is not on the list of substances pharmacies may compound from.
- Is there human evidence for BPC-157?
- Very little. There are no published randomised controlled trials. Human data are limited to small case series and a two-person pilot safety study.
- Is BPC-157 banned in sport?
- Yes. It is named under WADA's S0 non-approved substances category and is prohibited at all times.
- Does BPC-157 work for everyone who tries it?
- No. Many confessions describe recovery, but a meaningful share report no effect after full courses. Anecdotes cannot separate the peptide from time, rehab or other compounds.
- How many BPC-157 reports are on this site?
- As of 11 November 2026, this hub lists 77 published reports. The heading count updates as new reports are published.
- Does this page give dosing or sourcing advice?
- No. This is not a dosing recommendation. The site does not name or recommend suppliers.
- Does BPC-157 affect testosterone?
- There are no human studies showing that BPC-157 raises or lowers testosterone. Its effects on hormones in people are unknown.
- Is BPC-157 hard on your liver?
- There is no human data on liver toxicity. Animal studies suggest it is not toxic to the liver, but unregulated products may contain contaminants, so liver safety in people is unknown.
- Does BPC-157 work immediately?
- There is no clinical evidence on how fast it works in people. Timelines in confessions vary widely, and many writers used it alongside other treatments or rest, which makes effects hard to attribute.
Sources
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.